Another study used an in vitro platform referred to as “Systematic Evolution of Ligands by Exponential enrichment (SELEX)” for selecting RNA aptamers against purified ARRB2 in the context of chronic myelogenous leukemia (CML) [72]. The gene discussed is ARRB2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.